þ
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2015.
|
o
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __________ to __________.
|
|
|
DELAWARE
|
74-2747608
|
(State or other jurisdiction of
|
(I.R.S. Employer
|
incorporation or organization)
|
Identification No.)
|
|
|
12212 TECHNOLOGY BLVD., AUSTIN, TEXAS
|
78727
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
þ
|
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if smaller reporting company)
|
|
Smaller reporting company
o
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit 10.1
|
|
Exhibit 10.2
|
|
Exhibit 10.3
|
|
|
|
|
|
|
|
|
|
EX-101 INSTANCE DOCUMENT
|
|
EX-101 SCHEMA DOCUMENT
|
|
EX-101 CALCULATION LINKBASE DOCUMENT
|
|
EX-101 DEFINITION LINKBASE DOCUMENT
|
|
EX-101 LABELS LINKBASE DOCUMENT
|
|
EX-101 PRESENTATION LINKBASE DOCUMENT
|
|
2013 Restructuring Plan
|
|
Twelve Months Ended
December 31, 2014
|
||
|
|
|
||
Non-cash impairment charges:
|
|
|
||
Inventory
|
|
$
|
1,183
|
|
Property and equipment
|
|
494
|
|
|
Goodwill
|
|
1,159
|
|
|
Employee separation costs
|
|
154
|
|
|
Facility exit costs
|
|
69
|
|
|
Other
|
|
41
|
|
|
Total charges
|
|
$
|
3,100
|
|
Recorded to cost of revenue
|
|
1,218
|
|
|
Recorded to restructuring costs
|
|
$
|
1,882
|
|
|
Amortized Cost
|
|
Gains in Accumulated Other Comprehensive Income
|
|
Losses in Accumulated Other Comprehensive Income
|
|
Estimated Fair Value
|
||||||||
Current:
|
|
|
|
|
|
|
|
||||||||
Cash equivalents
|
$
|
3,605
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,605
|
|
Government sponsored debt securities
|
6,003
|
|
|
3
|
|
|
—
|
|
|
6,006
|
|
||||
Non-government sponsored debt securities
|
4,000
|
|
|
—
|
|
|
(3
|
)
|
|
3,997
|
|
||||
Total current securities
|
13,608
|
|
|
3
|
|
|
(3
|
)
|
|
13,608
|
|
||||
Noncurrent:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Government sponsored debt securities
|
3,998
|
|
|
4
|
|
|
—
|
|
|
4,002
|
|
||||
Non-government sponsored debt securities
|
2,002
|
|
|
1
|
|
|
—
|
|
|
2,003
|
|
||||
Total noncurrent securities
|
6,000
|
|
|
5
|
|
|
—
|
|
|
6,005
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total available-for-sale securities
|
$
|
19,608
|
|
|
$
|
8
|
|
|
$
|
(3
|
)
|
|
$
|
19,613
|
|
|
Amortized Cost
|
|
Gains in Accumulated Other Comprehensive Income
|
|
Losses in Accumulated Other Comprehensive Income
|
|
Estimated Fair Value
|
||||||||
Current:
|
|
|
|
|
|
|
|
||||||||
Cash equivalents
|
$
|
3,569
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,569
|
|
Total current securities
|
3,569
|
|
|
—
|
|
|
—
|
|
|
3,569
|
|
||||
Noncurrent:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Government sponsored debt securities
|
10,000
|
|
|
—
|
|
|
(11
|
)
|
|
9,989
|
|
||||
Non-government sponsored debt securities
|
6,002
|
|
|
—
|
|
|
(16
|
)
|
|
5,986
|
|
||||
Total noncurrent securities
|
16,002
|
|
|
—
|
|
|
(27
|
)
|
|
15,975
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total available-for-sale securities
|
$
|
19,571
|
|
|
$
|
—
|
|
|
$
|
(27
|
)
|
|
$
|
19,544
|
|
|
Estimated Fair Value
|
||||||
|
June 30, 2015
|
|
December 31, 2014
|
||||
Due in one year or less
|
$
|
10,003
|
|
|
$
|
—
|
|
Due after one year through two years
|
6,005
|
|
|
15,975
|
|
||
|
$
|
16,008
|
|
|
$
|
15,975
|
|
|
June 30, 2015
|
|
December 31, 2014
|
||||
Parts and supplies
|
$
|
16,651
|
|
|
$
|
19,354
|
|
Work-in-progress
|
7,449
|
|
|
8,687
|
|
||
Finished goods
|
8,498
|
|
|
8,575
|
|
||
|
$
|
32,598
|
|
|
$
|
36,616
|
|
Level 1 –
|
Quoted prices in active markets for identical assets or liabilities.
|
Level 2 –
|
Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
Level 3 –
|
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
|
Fair Value Measurements as of June 30, 2015 Using
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Money Market funds
|
$
|
3,605
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,605
|
|
Government sponsored debt securities
|
—
|
|
|
10,008
|
|
|
—
|
|
|
10,008
|
|
||||
Non-government sponsored debt securities
|
—
|
|
|
6,000
|
|
|
—
|
|
|
6,000
|
|
|
Fair Value Measurements as of December 31, 2014 Using
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Money Market funds
|
$
|
3,569
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,569
|
|
Government sponsored debt securities
|
—
|
|
|
9,989
|
|
|
—
|
|
|
$
|
9,989
|
|
|||
Non-government sponsored debt securities
|
—
|
|
|
5,986
|
|
|
—
|
|
|
$
|
5,986
|
|
|
June 30, 2015
|
|
December 31, 2014
|
||||
Balance at beginning of year
|
$
|
49,619
|
|
|
$
|
50,738
|
|
Allocation in disposal of Brisbane, Australia business (See Note 2)
|
—
|
|
|
(1,159
|
)
|
||
Foreign currency translation adjustments
|
—
|
|
|
40
|
|
||
Balance at end of period
|
$
|
49,619
|
|
|
$
|
49,619
|
|
|
Finite-lived
|
|
Indefinite-lived
|
|
|
||||||||||||||
|
Technology, trade secrets and know-how
|
|
Customer lists and contracts
|
|
Other identifiable intangible assets
|
|
IP R&D
|
|
Total
|
||||||||||
2014
|
|
|
|
|
|
|
|
|
|
||||||||||
Balance as of December 31, 2013
|
$
|
29,676
|
|
|
$
|
7,952
|
|
|
$
|
1,880
|
|
|
$
|
40,100
|
|
|
$
|
79,608
|
|
Foreign currency translation adjustments
|
28
|
|
|
6
|
|
|
10
|
|
|
—
|
|
|
44
|
|
|||||
Balance as of December 31, 2014
|
29,704
|
|
|
7,958
|
|
|
1,890
|
|
|
40,100
|
|
|
79,652
|
|
|||||
Less: accumulated amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Accumulated amortization balance as of December 31, 2013
|
(16,272
|
)
|
|
(2,326
|
)
|
|
(715
|
)
|
|
—
|
|
|
(19,313
|
)
|
|||||
Amortization expense
|
(3,025
|
)
|
|
(753
|
)
|
|
(135
|
)
|
|
—
|
|
|
(3,913
|
)
|
|||||
Foreign currency translation adjustments
|
(28
|
)
|
|
(6
|
)
|
|
(10
|
)
|
|
—
|
|
|
(44
|
)
|
|||||
Accumulated amortization balance as of December 31, 2014
|
(19,325
|
)
|
|
(3,085
|
)
|
|
(860
|
)
|
|
—
|
|
|
(23,270
|
)
|
|||||
Net balance as of December 31, 2014
|
$
|
10,379
|
|
|
$
|
4,873
|
|
|
$
|
1,030
|
|
|
$
|
40,100
|
|
|
$
|
56,382
|
|
Weighted average life (in years)
|
10
|
|
|
11
|
|
|
11
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
||||||||||
2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Balance as of December 31, 2014
|
$
|
29,704
|
|
|
$
|
7,958
|
|
|
$
|
1,890
|
|
|
$
|
40,100
|
|
|
$
|
79,652
|
|
Removal of fully amortized assets
|
(702
|
)
|
|
(161
|
)
|
|
(238
|
)
|
|
—
|
|
|
(1,101
|
)
|
|||||
Balance as of June 30, 2015
|
29,002
|
|
|
7,797
|
|
|
1,652
|
|
|
40,100
|
|
|
78,551
|
|
|||||
Less: accumulated amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Accumulated amortization balance as of December 31, 2014
|
(19,325
|
)
|
|
(3,085
|
)
|
|
(860
|
)
|
|
—
|
|
|
(23,270
|
)
|
|||||
Amortization expense
|
(1,239
|
)
|
|
(372
|
)
|
|
(67
|
)
|
|
—
|
|
|
(1,678
|
)
|
|||||
Removal of fully amortized assets
|
702
|
|
|
161
|
|
|
238
|
|
|
—
|
|
|
1,101
|
|
|||||
Accumulated amortization balance as of June 30, 2015
|
(19,862
|
)
|
|
(3,296
|
)
|
|
(689
|
)
|
|
—
|
|
|
(23,847
|
)
|
|||||
Net balance as of June 30, 2015
|
$
|
9,140
|
|
|
$
|
4,501
|
|
|
$
|
963
|
|
|
$
|
40,100
|
|
|
$
|
54,704
|
|
Weighted average life (in years)
|
10
|
|
|
11
|
|
|
11
|
|
|
|
|
|
|
|
2015 (six months)
|
$
|
1,554
|
|
2016
|
3,100
|
|
|
2017
|
2,144
|
|
|
2018
|
1,954
|
|
|
2019
|
1,954
|
|
|
Thereafter
|
3,898
|
|
|
|
14,604
|
|
|
IP R&D
|
40,100
|
|
|
|
$
|
54,704
|
|
|
Foreign Currency Items
|
|
Available for Sale Investments
|
|
Accumulated Other Comprehensive Loss Items
|
||||||
Balance as of December 31, 2014
|
$
|
(727
|
)
|
|
$
|
(17
|
)
|
|
$
|
(744
|
)
|
Other comprehensive (loss) income before reclassifications
|
(355
|
)
|
|
22
|
|
|
(333
|
)
|
|||
Amounts reclassified from accumulated other comprehensive income (loss)
|
—
|
|
|
—
|
|
|
—
|
|
|||
Net current-period other comprehensive (loss) income
|
(355
|
)
|
|
22
|
|
|
(333
|
)
|
|||
Balance as of June 30, 2015
|
$
|
(1,082
|
)
|
|
$
|
5
|
|
|
$
|
(1,077
|
)
|
|
Three Months Ended June 30, 2015
|
|
Six Months Ended June 30, 2015
|
||||||||||||||||||||
|
Before Tax
|
|
Tax Benefit
|
|
Net of Tax
|
|
Before Tax
|
|
Tax Benefit
|
|
Net of Tax
|
||||||||||||
Foreign currency translation adjustments
|
$
|
119
|
|
|
$
|
—
|
|
|
$
|
119
|
|
|
$
|
(355
|
)
|
|
$
|
—
|
|
|
$
|
(355
|
)
|
Unrealized losses on available-for-sale investments
|
1
|
|
|
—
|
|
|
1
|
|
|
34
|
|
|
(12
|
)
|
|
22
|
|
||||||
Other comprehensive income (loss)
|
$
|
120
|
|
|
$
|
—
|
|
|
$
|
120
|
|
|
$
|
(321
|
)
|
|
$
|
(12
|
)
|
|
$
|
(333
|
)
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Numerator:
|
|
|
|
|
|
|
|
||||||||
Net income
|
$
|
2,629
|
|
|
$
|
4,725
|
|
|
$
|
10,082
|
|
|
$
|
10,691
|
|
Denominator:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Denominator for basic net income per share - weighted average common stock outstanding
|
42,093
|
|
|
41,560
|
|
|
41,984
|
|
|
41,384
|
|
||||
Effect of dilutive securities: stock options and awards
|
197
|
|
|
565
|
|
|
162
|
|
|
479
|
|
||||
Denominator for diluted net income per share - weighted average shares outstanding - diluted
|
42,290
|
|
|
42,125
|
|
|
42,146
|
|
|
41,863
|
|
||||
Basic net income per share
|
$
|
0.06
|
|
|
$
|
0.11
|
|
|
$
|
0.24
|
|
|
$
|
0.26
|
|
Diluted net income per share
|
$
|
0.06
|
|
|
$
|
0.11
|
|
|
$
|
0.24
|
|
|
$
|
0.26
|
|
Stock Options (shares in thousands)
|
Shares
|
|
Weighted Average Exercise Price
|
|||
Outstanding as of December 31, 2014
|
825
|
|
|
$
|
18.84
|
|
Granted
|
962
|
|
|
15.94
|
|
|
Exercised
|
(15
|
)
|
|
7.48
|
|
|
Cancelled or expired
|
(15
|
)
|
|
16.98
|
|
|
Outstanding as of June 30, 2015
|
1,757
|
|
|
$
|
17.36
|
|
Restricted Stock Awards (shares in thousands)
|
Shares
|
|
Weighted Average Grant Price
|
|||
Non-vested as of December 31, 2014
|
1,098
|
|
|
$
|
19.63
|
|
Granted
|
276
|
|
|
15.95
|
|
|
Vested
|
(319
|
)
|
|
19.17
|
|
|
Cancelled or expired
|
(133
|
)
|
|
19.45
|
|
|
Non-vested as of June 30, 2015
|
922
|
|
|
$
|
18.72
|
|
|
|
|
|
|||
Restricted Stock Units (in thousands)
|
Shares
|
|
|
|
||
Non-vested as of December 31, 2014
|
658
|
|
|
|
|
|
Granted
|
122
|
|
|
|
|
|
Vested
|
(53
|
)
|
|
|
|
|
Cancelled or expired
|
(186
|
)
|
|
|
|
|
Non-vested as of June 30, 2015
|
541
|
|
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Cost of revenue
|
$
|
270
|
|
|
$
|
303
|
|
|
$
|
504
|
|
|
$
|
510
|
|
Research and development
|
733
|
|
|
736
|
|
|
980
|
|
|
1,136
|
|
||||
Selling, general and administrative
|
2,087
|
|
|
1,762
|
|
|
3,185
|
|
|
2,784
|
|
||||
Stock-based compensation costs reflected in net income
|
$
|
3,090
|
|
|
$
|
2,801
|
|
|
$
|
4,669
|
|
|
$
|
4,430
|
|
|
June 30, 2015
|
|
December 31, 2014
|
||||
Compensation and employee benefits
|
$
|
6,913
|
|
|
$
|
9,960
|
|
Litigation settlement
|
7,100
|
|
|
—
|
|
||
Income and other taxes
|
565
|
|
|
870
|
|
||
Warranty costs
|
369
|
|
|
488
|
|
||
Other
|
2,358
|
|
|
2,800
|
|
||
|
$
|
17,305
|
|
|
$
|
14,118
|
|
Accrued warranty costs as of December 31, 2014
|
$
|
488
|
|
Warranty adjustments/settlements
|
(324
|
)
|
|
Accrual for warranty costs
|
205
|
|
|
Accrued warranty costs as of June 30, 2015
|
$
|
369
|
|
•
|
risks and uncertainties relating to market demand and acceptance of our products and technology in development, including ARIES and NxTAG;
|
•
|
the uncertainty relating to increased focus on direct sales to the end user;
|
•
|
dependence on strategic partners for development, commercialization and distribution of products;
|
•
|
concentration of our revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating our technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges;
|
•
|
the timing of and process for regulatory approvals;
|
•
|
the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of our partners and end users and their ability to finance purchases of our products;
|
•
|
fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, fluctuations in bulk purchases of consumables, fluctuations in product mix, and the seasonal nature of some of our assay products;
|
•
|
our ability to obtain and enforce intellectual property protections on our products and technologies;
|
•
|
risks and uncertainties associated with implementing our acquisition strategy, including our ability to obtain financing, our ability to integrate acquired companies or selected assets into our consolidated business operations, and the ability to recognize the benefits of our acquisitions;
|
•
|
reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products;
|
•
|
our ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels;
|
•
|
changes in principal members of our management staff;
|
•
|
potential shortages, or increases in costs, of components or other disruptions to our manufacturing operations;
|
•
|
competition and competitive technologies utilized by our competitors;
|
•
|
our ability to successfully launch new products in a timely manner;
|
•
|
our increasing dependency on information technology to enable us to improve the effectiveness of our operations and to monitor financial accuracy and efficiency;
|
•
|
the implementation, including any modification, of our strategic operating plans;
|
•
|
the uncertainty regarding the outcome or expense of any litigation brought against or initiated by us; and
|
•
|
risks relating to our foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies.
|
•
|
Assay revenue is generated from the sale of our assay products which are a combination of chemical and biological reagents and our proprietary xMAP bead technology used to perform diagnostic and research assays on samples as well as real-time PCR and multiplexed PCR assays using our proprietary MultiCode technology.
|
•
|
System revenue is generated from the sale of our xMAP multiplexing analyzers and peripherals.
|
•
|
Consumable revenue is generated from the sale of our dyed polystyrene microspheres, along with sheath and drive fluid. Our larger commercial and development partners often purchase these consumables in bulk to minimize the number of incoming qualification events and to allow for longer development and production runs.
|
•
|
Royalty revenue is generated when a partner sells our proprietary microspheres to an end user, when a partner sells a kit incorporating our proprietary microspheres to an end user or when a partner utilizes a kit to provide a testing result to a user. End users can be facilities such as testing labs, development facilities and research facilities that buy prepared kits and have specific testing needs or testing service companies that provide assay testing results to pharmaceutical research companies or physicians.
|
•
|
Service revenue is generated when a partner or other owner of a system purchases a service contract from us after the standard warranty has expired or pays us for our time and materials to service instruments. Service contract revenue is amortized over the life of the contract and the costs associated with those contracts are recognized as incurred.
|
•
|
Other revenue consists of items such as training, shipping, parts sales, license revenue, grant revenue, contract research and development fees, milestone revenue and other items that individually amount to less than 5% of total revenue.
|
•
|
Consolidated revenue was
$58.9 million
for the quarter ended
June 30, 2015
, representing a
6%
increase over revenue for the
second
quarter of
2014
.
|
•
|
Assay revenue of
$24.2 million
for the quarter ended
June 30, 2015
, representing a
22%
increase over assay revenue for the
second
quarter of
2014
. Infectious disease sales comprised approximately
66%
of total assay sales, with genetic testing sales representing
34%
of total assay sales.
|
•
|
Partners reported
$121.2 million
of royalty bearing end user sales on xMAP technology for the quarter, a
6%
increase over the
second
quarter of
2014
, contributing to the
17%
increase in royalty revenue from the
second
quarter of
2014
.
|
•
|
80%
of consolidated revenue was attributable to our recurring revenue streams (consumable sales, royalty revenue and assay sales).
|
•
|
Began clinical trials for ARIES Group B Streptococcus Assay and ARIES Clostridium difficile Assay.
|
•
|
Shipments of
234
multiplexing analyzers, which included
94
Luminex® 100/200
TM
systems,
119
MAGPIX® systems and
21
FLEXMAP 3D® systems.
|
•
|
Launched the Research Use Only NxTAG Respiratory Pathogen Panel that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodate the higher throughput required to respond to seasonal changes in demand.
|
•
|
clinical validation and preparation for commercial launch of our ARIES system, the next generation sample-to-answer platform for our MultiCode-RTx technology, including in vitro diagnostic (IVD) assays;
|
•
|
development of a pipeline of assays for the ARIES system menu;
|
•
|
development of the next generation multiplex chemistry, including the next generation of our Respiratory Viral Panel line of IVD assays;
|
•
|
continued execution of our pharmacogenetic strategy;
|
•
|
continued execution of our direct sales strategy, including developing the infrastructure necessary to support our sales force, decreasing reliance on our distributors outside of the U.S.;
|
•
|
commercialization, regulatory clearance and market adoption of products, including commercialization of MultiCode analyte specific reagents outside of the United States;
|
•
|
maintenance and improvement of our existing products and the timely development, completion and successful commercial launch of our pipeline products;
|
•
|
expansion and enhancement of our installed base and our market position within our identified target market segments;
|
•
|
adoption and use of our platforms and consumables by our customers for their testing services;
|
•
|
monitoring and mitigating the effect of the ongoing uncertainty in global finance markets and changes in government funding on planned purchases by end users; and
|
•
|
continued adoption and development of partner products incorporating Luminex technology through effective partner management.
|
|
Three Months Ended June 30,
|
|
|
|
|
|||||||||
|
2015
|
|
2014
|
|
Variance
|
|
Variance (%)
|
|||||||
Revenue
|
$
|
58,917
|
|
|
$
|
55,632
|
|
|
$
|
3,285
|
|
|
6
|
%
|
Gross profit
|
$
|
43,270
|
|
|
$
|
38,147
|
|
|
5,123
|
|
|
13
|
%
|
|
Gross margin percentage
|
73
|
%
|
|
69
|
%
|
|
4
|
%
|
|
N/A
|
|
|||
Operating expenses
|
$
|
33,311
|
|
|
$
|
33,376
|
|
|
(65
|
)
|
|
—
|
%
|
|
Income from operations
|
$
|
9,959
|
|
|
$
|
4,771
|
|
|
5,188
|
|
|
109
|
%
|
|
Six Months Ended June 30,
|
|
|
|
|
|||||||||
|
2015
|
|
2014
|
|
Variance
|
|
Variance (%)
|
|||||||
Revenue
|
$
|
116,658
|
|
|
$
|
112,193
|
|
|
$
|
4,465
|
|
|
4
|
%
|
Gross profit
|
$
|
83,489
|
|
|
$
|
78,101
|
|
|
5,388
|
|
|
7
|
%
|
|
Gross margin percentage
|
72
|
%
|
|
70
|
%
|
|
2
|
%
|
|
N/A
|
|
|||
Operating expenses
|
$
|
63,837
|
|
|
$
|
65,145
|
|
|
(1,308
|
)
|
|
(2
|
)%
|
|
Income from operations
|
$
|
19,652
|
|
|
$
|
12,956
|
|
|
6,696
|
|
|
(52
|
)%
|
|
June 30, 2015
|
|
December 31, 2014
|
||||
|
(in thousands)
|
||||||
Cash and cash equivalents
|
$
|
111,064
|
|
|
$
|
91,694
|
|
Short-term investments
|
10,003
|
|
|
—
|
|
||
Long-term investments
|
6,005
|
|
|
15,975
|
|
||
|
$
|
127,072
|
|
|
$
|
107,669
|
|
ISSUER PURCHASES OF EQUITY SECURITIES
|
|||||||||||||
Period
|
Total Number of Shares Purchased (1)
|
|
Average Price Paid per Share
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
|
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
|
||||||
4/1/15 - 4/30/15
|
108
|
|
|
$
|
16.06
|
|
|
—
|
|
|
$
|
—
|
|
5/1/15 - 5/31/15
|
166
|
|
|
17.00
|
|
|
—
|
|
|
—
|
|
||
6/1/15 - 6/30/15
|
1,181
|
|
|
17.21
|
|
|
—
|
|
|
—
|
|
||
Total Second Quarter
|
1,455
|
|
|
$
|
17.10
|
|
|
—
|
|
|
$
|
—
|
|
(1)
Total shares purchased are attributable to the withholding of shares by Luminex to satisfy the payment of tax obligations related to the vesting of restricted shares.
|
Exhibit
Number
|
|
Description of Documents
|
|
|
|
10.1#
|
|
Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan (Previously filed as Annex A to the Company's Proxy Statement for its Annual Meeting of Stockholders held on May 14, 2015).
|
|
|
|
10.2#
|
|
Form of Restricted Share Award Agreement for Directors for the Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan.
|
|
|
|
10.3#
|
|
Form of Restricted Share Unit Agreement for Directors for the Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan.
|
|
|
|
31.1
|
|
Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
31.2
|
|
Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1
|
|
Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.2
|
|
Certification by CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
101
|
|
The following materials from Luminex Corporation's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Statement of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements.
|
|
|
|
#
|
|
Management contract or compensatory plan or arrangement.
|
Exhibit
Number
|
|
Description of Documents
|
|
|
|
10.1#
|
|
Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan (Previously filed as Annex A to the Company's Proxy Statement for its Annual Meeting of Stockholders held on May 14, 2015.
|
|
|
|
10.2#
|
|
Form of Restricted Share Award Agreement for Directors for the Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan.
|
|
|
|
10.3#
|
|
Form of Restricted Share Unit Agreement for Directors for the Luminex Corporation Third Amended and Restated 2006 Equity Incentive Plan.
|
|
|
|
31.1
|
|
Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
31.2
|
|
Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1
|
|
Certification by CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.2
|
|
Certification by CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
101
|
|
The following materials from Luminex Corporation's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015, formatted in XBRL: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Statement of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements.
|
|
|
|
#
|
|
Management contract or compensatory plan or arrangement.
|
To the Company
:
|
Luminex Corporation
|
To the Grantee
:
|
The address then maintained with respect to the Grantee in the Company's records.
|
To the Company
:
|
Luminex Corporation
|
To the Grantee
:
|
The address then maintained with respect to the Grantee in the Company's records.
|